This conference is the leading global conference on anti-microbial resistance. The event brings together government authorities, pharma, biotechs, diagnostics providers, hospitals, funding agencies, academia, laboratories and payers to discuss the urgent need for the development of novel and new classes of antibiotics, the application of responsible antimicrobial stewardship guidelines and the advances in diagnostics.

The world is now faced with an opportunity to curb Anti-Microbial Resistance while leveraging the benefits of an incentivized industry that can save millions of lives while transforming the way infectious diseases are treated. We are entering a new era of treating infectious diseases.

With funding for antibiotic R&D on the rise, the discussion now moves into the real incentives for the commercialization of antibiotics, the application of innovative diagnostics technologies and the collaboration between industry and physicians community to improve stewardship practices.